DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SAKAR HEALTHCARE LIMITED (SAKAR) share price today?

SAKAR HEALTHCARE LIMITED (SAKAR) is trading at ₹877.7 on the NSE, down 2.15% on the day. Source: DocStoX.

What is the PE ratio of SAKAR HEALTHCARE LIMITED?

SAKAR HEALTHCARE LIMITED has a price-to-earnings (PE) ratio of 110.1 in the Healthcare sector.

What is the market capitalisation of SAKAR HEALTHCARE LIMITED?

SAKAR HEALTHCARE LIMITED has a market capitalisation of approximately ₹0 crore.

SAKAR HEALTHCARE LIMITED

SAKAR·NSE·Healthcare

₹877.70▼ -19.25 (-2.15%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹861.35

₹908.05

52W₹311

₹96087%

Open

₹900.00

High

₹908.05

Low

₹861.35

Prev Close

₹896.95

Volume

1.28L

VWAP

₹877.17

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

110.13Expensive

P/B Ratio

5.49

EPS

₹7.97

Book Value

₹145.82

ROE

10.00%Average

ROCE

9.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.22Low

Face Value

₹10.00

52W High

₹960.00

52W Low

₹311.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹142

▼ 83.9%downside

Trading at ₹878 — 84% above our estimate

BearFair valueBull

₹120₹142₹163

/100

Business quality — Watch the fundamentals

Growth 65Profitability 35Efficiency 3Valuation 45

Plain English

Our view

A steady, established business
Low debt relative to equity
Expensive — trades at 110× earnings

Strengths

Low debt relative to equity
Profit growing 20% a year
Promoters hold a controlling stake

Risks

Expensive — trades at 110× earnings
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹146 book

₹136

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹162

Analyst target

No analyst coverage

—

Blended fair value₹142

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Profit growing 20% a year
Promoters hold a controlling stake

Bear case

Expensive — trades at 110× earnings
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

110.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

10.0%Average

Above 15% is considered healthy for Indian equities

ROCE

9.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.22Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

5.49

EPS

₹7.97

Div Yield

—

What changed

Recent changes

Foreign investors+12.9% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 110.1×

Growth

Strong

+24% rev CAGR

Profitability

Modest

10.0% ROE

Financial health

Rock solid

D/E 0.22

Momentum

N/A

No technicals

Today

Trading activity

Delivery %44.7%

Turnover₹1123.52L Cr

Trades9,110

VWAP₹877.17

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+23.7%

+21.5%

10Y

+19.9%

Profit

+32.9%

+22.6%

10Y

+31.3%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is expected to give good quarter
Company has delivered good profit growth of 23.1% CAGR over last 5 years
Company's median sales growth is 18.0% of last 10 years

Watch-outs

Cons

Stock is trading at 5.65 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 7.49% over last 3 years.
Promoter holding has decreased over last 3 years: -7.86%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 12.94 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

53%

Promoter

Promoters

52.9%0.00

Public

18.1%+1.52

FII / FPI

12.9%+12.94

DII

11.3%-0.04

Others

4.8%

Total shareholders

9,580+2,511 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter52.86%

FII12.94%

DII11.32%

Public18.11%

Others4.77%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]